Design, synthesis chalcone derivatives as AdipoR agonist for type 2 diabetes.
Two structurally novel series of chalcone derivatives were designed and synthesized as potential agents against type 2 diabetes. As a result of the antidiabetic biological evaluation in streptozotocin (STZ)-induced type 2 diabetes animal model, 13e, 13g, and 19f showed more significant reduction in serum Glu, TG, TC levels by contrast to the positive control AdipoRon. In addition to upregulating the expression of AdipoR1 and AdipoR2, 13e and 19f treatment also increased expression of AMPK and PPAR-α. Taken together, these results suggested that 13e and 19f might be a promising compound for type 2 diabetes treatment.
['Zhu|Panhu|P|http://orcid.org/0000-0001-5440-4391', 'Huang|Weijun|W|http://orcid.org/0000-0003-2202-0574', 'Li|Jiaming|J|http://orcid.org/0000-0003-2141-7561', 'Ma|Xiaodong|X|', 'Hu|Mengqi|M|', 'Wang|Yujun|Y|', 'Xu|Qinlong|Q|', 'Wang|Xianna|X|']
D055372:AMP-Activated Protein Kinases D000818:Animals D002460:Cell Line D047188:Chalcones D002784:Cholesterol D003921:Diabetes Mellitus, Experimental D015195:Drug Design D007004:Hypoglycemic Agents D051379:Mice D008810:Mice, Inbred C57BL D047493:PPAR alpha D010880:Piperidines D054419:Receptors, Adiponectin D014280:Triglycerides
chalcone derivatives adipoR type 2 diabetes expression